Literature DB >> 29350789

TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence.

Timothy T Spear1, Kendra C Foley1, Elizabeth Garrett-Mayer2,3, Michael I Nishimura1.   

Abstract

T cell receptor (TCR) gene-modified T cells are a promising immunotherapy but require refinement to improve clinical responses and limit off-target toxicities. A variety of TCR and gene-delivery vector modifications have been developed to enhance introduced TCR expression and limit introduced/endogenous TCR chain mispairing, improving target antigen recognition and minimizing mispairing-induced cross-reactivity. Using our well-characterized HCV1406 TCR, we previously compared the impact of various chain pairing enhancing modifications on TCR expression and cognate antigen recognition. HCV1406 TCR is also natively cross-reactive against naturally occurring altered peptide ligands (APLs), which was shown to be dependent on high TCR surface density. In this report, we observed in a Jurkat model that absent TCR chain pairing competition alleviated CD8-dependent APL recognition and induced novel cross-reactivity of HCV1406 TCR. We then compared chain pairing enhancing modifications' effects on TCR cross-reactivity in Jurkat and T cells, showing C-terminal leucine zippers and constant region murinization alleviated CD8 dependence and induced novel APL recognition. While modifications enhancing TCR chain pairing intend to avoid cross-reactivity by limiting mispairing with the endogenous TCR, these data suggest they may also enhance natural cross-reactivity and reduce dependence on CD8. These observations have significant implications on the design/implementation of TCR gene-modified T cells. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  T cell; T cell receptor; adoptive cell therapy; altered peptide ligands; chain pairing; gene-modified T cells

Mesh:

Substances:

Year:  2018        PMID: 29350789      PMCID: PMC6133711          DOI: 10.1002/JLB.5A0817-314R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  33 in total

1.  Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.

Authors:  Timothy T Spear; Timothy P Riley; Gretchen E Lyons; Glenda G Callender; Jeffrey J Roszkowski; Yuan Wang; Patricia E Simms; Gina M Scurti; Kendra C Foley; David C Murray; Lance M Hellman; Rachel H McMahan; Makio Iwashima; Elizabeth Garrett-Mayer; Hugo R Rosen; Brian M Baker; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2016-02-26       Impact factor: 4.962

2.  Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells.

Authors:  Gretchen E Lyons; Tamson Moore; Natasha Brasic; Mingli Li; Jeffrey J Roszkowski; Michael I Nishimura
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

3.  A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments.

Authors:  H C Chang; Z Bao; Y Yao; A G Tse; E C Goyarts; M Madsen; E Kawasaki; P P Brauer; J C Sacchettini; S G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

4.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer.

Authors:  Elena Provasi; Pietro Genovese; Angelo Lombardo; Zulma Magnani; Pei-Qi Liu; Andreas Reik; Victoria Chu; David E Paschon; Lei Zhang; Jurgen Kuball; Barbara Camisa; Attilio Bondanza; Giulia Casorati; Maurilio Ponzoni; Fabio Ciceri; Claudio Bordignon; Philip D Greenberg; Michael C Holmes; Philip D Gregory; Luigi Naldini; Chiara Bonini
Journal:  Nat Med       Date:  2012-05       Impact factor: 53.440

5.  Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.

Authors:  Peter Meyerhuber; Heinke Conrad; Lilian Stärck; Matthias Leisegang; Dirk H Busch; Wolfgang Uckert; Helga Bernhard
Journal:  J Mol Med (Berl)       Date:  2010-08-11       Impact factor: 4.599

6.  T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

Authors:  Maria R Parkhurst; James C Yang; Russell C Langan; Mark E Dudley; Debbie-Ann N Nathan; Steven A Feldman; Jeremy L Davis; Richard A Morgan; Maria J Merino; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Giao Q Phan; Ramona M Lim; Stephen A Wank; Nicholas P Restifo; Paul F Robbins; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

7.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.

Authors:  Gavin M Bendle; Carsten Linnemann; Anna I Hooijkaas; Laura Bies; Moniek A de Witte; Annelies Jorritsma; Andrew D M Kaiser; Nadine Pouw; Reno Debets; Elisa Kieback; Wolfgang Uckert; Ji-Ying Song; John B A G Haanen; Ton N M Schumacher
Journal:  Nat Med       Date:  2010-04-18       Impact factor: 53.440

8.  Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

Authors:  Sachiko Okamoto; Junichi Mineno; Hiroaki Ikeda; Hiroshi Fujiwara; Masaki Yasukawa; Hiroshi Shiku; Ikunoshin Kato
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

Review 9.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

10.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

View more
  7 in total

1.  Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.

Authors:  Raphaëlle Toledano Zur; Galit Adler; Katerina Shamalov; Yair Tal; Chen Ankri; Cyrille J Cohen
Journal:  Exp Suppl       Date:  2022

Review 2.  Engineering the T cell receptor for fun and profit: Uncovering complex biology, interrogating the immune system, and targeting disease.

Authors:  Aaron M Rosenberg; Brian M Baker
Journal:  Curr Opin Struct Biol       Date:  2022-03-25       Impact factor: 7.786

Review 3.  The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.

Authors:  Diana Campillo-Davo; Donovan Flumens; Eva Lion
Journal:  Cells       Date:  2020-07-18       Impact factor: 6.600

4.  Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.

Authors:  Roslin Y Docta; Tiago Ferronha; Joseph P Sanderson; Thomas Weissensteiner; George R Pope; Alan D Bennett; Nicholas J Pumphrey; Zoltan Ferjentsik; Laura L Quinn; Guy E Wiedermann; Victoria E Anderson; Manoj Saini; Miguel Maroto; Elliot Norry; Andrew B Gerry
Journal:  Hepatology       Date:  2019-02-14       Impact factor: 17.425

Review 5.  Safety and Tolerability of Adoptive Cell Therapy in Cancer.

Authors:  Benita Wolf; Stefan Zimmermann; Caroline Arber; Melita Irving; Lionel Trueb; George Coukos
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.228

6.  Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.

Authors:  Masaki Maruta; Toshiki Ochi; Kazushi Tanimoto; Hiroaki Asai; Takashi Saitou; Hiroshi Fujiwara; Takeshi Imamura; Katsuto Takenaka; Masaki Yasukawa
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

Review 7.  Genetic Modification of T Cells for the Immunotherapy of Cancer.

Authors:  Suzanne Quinn; Natasha Lenart; Victoria Dronzek; Gina M Scurti; Nasheed M Hossain; Michael I Nishimura
Journal:  Vaccines (Basel)       Date:  2022-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.